Skip to main content
Premium Trial:

Request an Annual Quote

Isis to Receive $1.4M from Alnylam Following Monsanto Deal

Premium

Isis Pharmaceuticals this week said it will receive a $1.4 million payment from Alnylam following that company's establishment of a technology- and intellectual property-licensing deal with agbio firm Monsanto.

Last week, Alnylam announced that it has struck a deal giving Monsanto exclusive, worldwide rights to its RNAi technology and IP for agricultural applications (GSN 9/6/2012).

In 2004, Alnylam and Isis forged an IP arrangement, with each gaining access to the others' IP for use in their respective fields (GSN 3/19/2004). Pursuant to the terms of that arrangement, Isis stands to receive $1.4 million of the $29.2 million that Alnylam received upfront from Monsanto, as well as an undisclosed portion of future milestones and royalties.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.